Tag: Doras

Approximately 30% to 40% of adults in the U.S. report symptoms of insomnia each year. In response, pharmacology has evolved, leading to a key question for many: **What is the new class of drugs for insomnia?** The answer lies in Dual Orexin Receptor Antagonists (DORAs), which offer a novel approach to treatment.

According to the CDC, in 2020, 14.5% of adults had trouble falling asleep and 17.8% had trouble staying asleep most days [1.10.1]. For those seeking alternatives, the question often arises: **what is stronger than Ambien for insomnia?** Several classes of medication may offer more potent effects.

In January 2025, the FDA approved Journavx (suzetrigine), the first new class of pain reliever in over two decades, which also has a relaxing effect by modulating pain signals. This and other recent advancements are reshaping the answer to the question: **What is the new relax medicine?**